Year In Review 2021

The Surfers and guests discuss key lessons learned in 2020 about Drugs and Diagnostics, and Patient Treatment and Perspectives.

S2-E62 – 2021 NAFLD Year-in-Review

SurfingNASH’s 2021 NAFLD year-in-review looks at artificial intelligence, non-invasive testing and patient activism.

S2-E63: Surfing NASH's 2021 NAFLD Year-in-Review: Part 2

S2-E63 – Manal Abdelmalek, Ken Cusi And Jörn Schattenberg Join SurfingNASH’s 2021 NAFLD Year-in-Review

Surfing NASH’s 2021 NAFLD year-in-review looks at the roles of older and newer drugs, multi-specialty integration against the coming NASH pandemic, and cost-effective, patient-focused healthcare.

S2-E63.1 – SurfingNASH’s 2021 NAFLD year-in-review Covers Cirrhosis Treatment Strategies Today and NASH Drugs in Development

Manal Abdelmalek joins the Surfers to discuss strategies for treating cirrhotic patients today and how NASH drug development and disease knowledge will improve treatment over time.

S2-E63.2 – SurfingNASH’s 2021 NAFLD year-in-review Covers NASH Multidisciplinary Initiatives and the Clinical Care Pathways Paper

This conversation is part of SurfingNASH’s 2021 NAFLD Year-In-Review. Professor Kenneth Cusi of the University of Florida joins Louise Campbell and Roger Green to discuss

S2-E63.3 – SurfingNASH’s 2021 NAFLD year-in-review Covers NASH Cost Effectiveness and Quality-of-Life

Jörn Schattenberg joins the Surfers to discuss the NASH cost-effectiveness research and related findings on quality of life.

S2-E64 – 2021 NAFLD Year in Review – Part 3

The last half of December marks our annual NAFLD Year-in-Review. Episodes 62-64 each include ~20 minute segments of longer interviews with Stakeholders who have made a dent in Fatty Liver disease in 2021.